Nano Letters:新型抗癌纳米技术可直接将药物运输至肿瘤“心脏”发挥作用

2015-04-15 佚名 生物谷

近日,发表在国际杂志Nano Letters上的一篇研究论文中,来自韩国科学技术研究所的研究人员通过研究开发了一种新型高效的抗癌纳米技术,其可以将抗癌药物均匀地运输至整个肿瘤组织。科学家们常常利用抗癌药物来治疗不能进行手术的肿瘤,然而将药物运输至肿瘤细胞通常比较困难,尤其是将药物覆盖整个肿瘤组织更是难如登天;利用前的药物运输系统,比如纳米技术,一种药物就可以被仅仅运输到血管附近的肿瘤细胞处,但对肿



近日,发表在国际杂志Nano Letters上的一篇研究论文中,来自韩国科学技术研究所的研究人员通过研究开发了一种新型高效的抗癌纳米技术,其可以将抗癌药物均匀地运输至整个肿瘤组织。

科学家们常常利用抗癌药物来治疗不能进行手术的肿瘤,然而将药物运输至肿瘤细胞通常比较困难,尤其是将药物覆盖整个肿瘤组织更是难如登天;利用前的药物运输系统,比如纳米技术,一种药物就可以被仅仅运输到血管附近的肿瘤细胞处,但对肿瘤核心细胞却毫发无损;大多数的药物都是通过注射到血液中发挥作用的,而这种情况经常会导致肿瘤的复发。

本文研究中,研究者利用脂质体,使其融合如细胞膜并且进入到细胞内部,这样位于脂质体内部的药物就可以随着血流达到患处,进入到血管附近的肿瘤细胞,在肿瘤细胞中其被装载于外核体中,外核体机体中天然发生的纳米颗粒,其可以在细胞间转运,这样药物就可以被有效运输至核心的肿瘤细胞了。

外核体是由细胞分泌产生的,其存在于肿瘤的微环境中,被认为和肿瘤的恶化及转移有直接关联,本文中研究小组就开始利用外核体来将抗癌药物运输至核心的肿瘤细胞,首先研究者利用新型的运输技术将光敏感型的抗癌药物注射到实验小鼠机体中,随后以光照射肿瘤位点来激活抗癌疗法,同时对组织样本进行分析,最后研究者就获得了整个肿瘤组织的抗癌药物的作用效应。

本文研究结果为癌症药物运输的技术奠定了基础,相关研究也为后期科学家们开发更多有效的药物运输系统来治疗慢性疾病提供新的思路。当前研究者正在利用其它抗癌药物来构建实验,他们利用肿瘤穿透性药物运输纳米技术来鉴别抗癌药物对恶性肿瘤组织的效应,而依靠当前技术来实现这种目的是非常困难的。

最后Park教授说道,本文研究首次利用了生物性的纳米颗粒,即外核体,其可以被连续分泌产生,并且可以将原材料转移到附近的细胞中,而且可以将药物直接运输至肿瘤的“心脏”部位。

原始出处:

Junsung Lee ,Jiyoung Kim,Moonkyoung Jeong,et,al.Liposome-Based Engineering of Cells To Package Hydrophobic Compounds in Membrane Vesicles for Tumor Penetration.Nano Letters.March 25, 2015.(pdf:free)

版权声明:
本网站所有内容来源注明为“williamhill asia 医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于williamhill asia 医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“williamhill asia 医学”。其它来源的文章系转载文章,或“williamhill asia 号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与williamhill asia 联系,williamhill asia 将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1878098, encodeId=218c18e80983e, content=<a href='/topic/show?id=c157696175' target=_blank style='color:#2F92EE;'>#ERS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6961, encryptionId=c157696175, topicName=ERS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e93e105, createdName=anminleiryan, createdTime=Sun Aug 02 12:14:00 CST 2015, time=2015-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1650546, encodeId=da2f1650546ba, content=<a href='/topic/show?id=dbf18e8822b' target=_blank style='color:#2F92EE;'>#药物运输#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87882, encryptionId=dbf18e8822b, topicName=药物运输)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb1a24016888, createdName=zhao4624, createdTime=Fri Oct 23 07:14:00 CST 2015, time=2015-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2038383, encodeId=cd82203838380, content=<a href='/topic/show?id=f7c61e90472' target=_blank style='color:#2F92EE;'>#TTE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17904, encryptionId=f7c61e90472, topicName=TTE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96f62500201, createdName=12498e67m28暂无昵称, createdTime=Tue Feb 16 00:14:00 CST 2016, time=2016-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1521243, encodeId=1fb21521243a2, content=<a href='/topic/show?id=e96be73835c' target=_blank style='color:#2F92EE;'>#纳米技术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77383, encryptionId=e96be73835c, topicName=纳米技术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b1e911322397, createdName=windight, createdTime=Fri Apr 17 05:14:00 CST 2015, time=2015-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=21227, encodeId=c8932122ee0, content=离应用还远, beContent=null, objectType=article, channel=null, level=null, likeNumber=174, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=96871613250, createdName=medcardio, createdTime=Wed Apr 15 14:45:00 CST 2015, time=2015-04-15, status=1, ipAttribution=)]
    2015-08-02 anminleiryan
  2. [GetPortalCommentsPageByObjectIdResponse(id=1878098, encodeId=218c18e80983e, content=<a href='/topic/show?id=c157696175' target=_blank style='color:#2F92EE;'>#ERS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6961, encryptionId=c157696175, topicName=ERS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e93e105, createdName=anminleiryan, createdTime=Sun Aug 02 12:14:00 CST 2015, time=2015-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1650546, encodeId=da2f1650546ba, content=<a href='/topic/show?id=dbf18e8822b' target=_blank style='color:#2F92EE;'>#药物运输#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87882, encryptionId=dbf18e8822b, topicName=药物运输)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb1a24016888, createdName=zhao4624, createdTime=Fri Oct 23 07:14:00 CST 2015, time=2015-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2038383, encodeId=cd82203838380, content=<a href='/topic/show?id=f7c61e90472' target=_blank style='color:#2F92EE;'>#TTE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17904, encryptionId=f7c61e90472, topicName=TTE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96f62500201, createdName=12498e67m28暂无昵称, createdTime=Tue Feb 16 00:14:00 CST 2016, time=2016-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1521243, encodeId=1fb21521243a2, content=<a href='/topic/show?id=e96be73835c' target=_blank style='color:#2F92EE;'>#纳米技术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77383, encryptionId=e96be73835c, topicName=纳米技术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b1e911322397, createdName=windight, createdTime=Fri Apr 17 05:14:00 CST 2015, time=2015-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=21227, encodeId=c8932122ee0, content=离应用还远, beContent=null, objectType=article, channel=null, level=null, likeNumber=174, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=96871613250, createdName=medcardio, createdTime=Wed Apr 15 14:45:00 CST 2015, time=2015-04-15, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1878098, encodeId=218c18e80983e, content=<a href='/topic/show?id=c157696175' target=_blank style='color:#2F92EE;'>#ERS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6961, encryptionId=c157696175, topicName=ERS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e93e105, createdName=anminleiryan, createdTime=Sun Aug 02 12:14:00 CST 2015, time=2015-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1650546, encodeId=da2f1650546ba, content=<a href='/topic/show?id=dbf18e8822b' target=_blank style='color:#2F92EE;'>#药物运输#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87882, encryptionId=dbf18e8822b, topicName=药物运输)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb1a24016888, createdName=zhao4624, createdTime=Fri Oct 23 07:14:00 CST 2015, time=2015-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2038383, encodeId=cd82203838380, content=<a href='/topic/show?id=f7c61e90472' target=_blank style='color:#2F92EE;'>#TTE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17904, encryptionId=f7c61e90472, topicName=TTE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96f62500201, createdName=12498e67m28暂无昵称, createdTime=Tue Feb 16 00:14:00 CST 2016, time=2016-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1521243, encodeId=1fb21521243a2, content=<a href='/topic/show?id=e96be73835c' target=_blank style='color:#2F92EE;'>#纳米技术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77383, encryptionId=e96be73835c, topicName=纳米技术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b1e911322397, createdName=windight, createdTime=Fri Apr 17 05:14:00 CST 2015, time=2015-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=21227, encodeId=c8932122ee0, content=离应用还远, beContent=null, objectType=article, channel=null, level=null, likeNumber=174, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=96871613250, createdName=medcardio, createdTime=Wed Apr 15 14:45:00 CST 2015, time=2015-04-15, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1878098, encodeId=218c18e80983e, content=<a href='/topic/show?id=c157696175' target=_blank style='color:#2F92EE;'>#ERS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6961, encryptionId=c157696175, topicName=ERS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e93e105, createdName=anminleiryan, createdTime=Sun Aug 02 12:14:00 CST 2015, time=2015-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1650546, encodeId=da2f1650546ba, content=<a href='/topic/show?id=dbf18e8822b' target=_blank style='color:#2F92EE;'>#药物运输#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87882, encryptionId=dbf18e8822b, topicName=药物运输)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb1a24016888, createdName=zhao4624, createdTime=Fri Oct 23 07:14:00 CST 2015, time=2015-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2038383, encodeId=cd82203838380, content=<a href='/topic/show?id=f7c61e90472' target=_blank style='color:#2F92EE;'>#TTE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17904, encryptionId=f7c61e90472, topicName=TTE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96f62500201, createdName=12498e67m28暂无昵称, createdTime=Tue Feb 16 00:14:00 CST 2016, time=2016-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1521243, encodeId=1fb21521243a2, content=<a href='/topic/show?id=e96be73835c' target=_blank style='color:#2F92EE;'>#纳米技术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77383, encryptionId=e96be73835c, topicName=纳米技术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b1e911322397, createdName=windight, createdTime=Fri Apr 17 05:14:00 CST 2015, time=2015-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=21227, encodeId=c8932122ee0, content=离应用还远, beContent=null, objectType=article, channel=null, level=null, likeNumber=174, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=96871613250, createdName=medcardio, createdTime=Wed Apr 15 14:45:00 CST 2015, time=2015-04-15, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1878098, encodeId=218c18e80983e, content=<a href='/topic/show?id=c157696175' target=_blank style='color:#2F92EE;'>#ERS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6961, encryptionId=c157696175, topicName=ERS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e93e105, createdName=anminleiryan, createdTime=Sun Aug 02 12:14:00 CST 2015, time=2015-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1650546, encodeId=da2f1650546ba, content=<a href='/topic/show?id=dbf18e8822b' target=_blank style='color:#2F92EE;'>#药物运输#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87882, encryptionId=dbf18e8822b, topicName=药物运输)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb1a24016888, createdName=zhao4624, createdTime=Fri Oct 23 07:14:00 CST 2015, time=2015-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2038383, encodeId=cd82203838380, content=<a href='/topic/show?id=f7c61e90472' target=_blank style='color:#2F92EE;'>#TTE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17904, encryptionId=f7c61e90472, topicName=TTE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96f62500201, createdName=12498e67m28暂无昵称, createdTime=Tue Feb 16 00:14:00 CST 2016, time=2016-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1521243, encodeId=1fb21521243a2, content=<a href='/topic/show?id=e96be73835c' target=_blank style='color:#2F92EE;'>#纳米技术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77383, encryptionId=e96be73835c, topicName=纳米技术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b1e911322397, createdName=windight, createdTime=Fri Apr 17 05:14:00 CST 2015, time=2015-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=21227, encodeId=c8932122ee0, content=离应用还远, beContent=null, objectType=article, channel=null, level=null, likeNumber=174, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=96871613250, createdName=medcardio, createdTime=Wed Apr 15 14:45:00 CST 2015, time=2015-04-15, status=1, ipAttribution=)]
    2015-04-15 medcardio

    离应用还远

    0

相关威廉亚洲官网

Cell:假性基因也可致癌

在过去几年里,科学家们在长非编码RNA功能研究方面取得了显著进展,lncRNA作为多种生物学过程的重要调控因子,目前已经发现其在多种疾病过程如癌症的发展过程中具有重要作用。   近日,来自美国哈佛大学医学院的研究人员在著名国际学术期刊cell在线发表了他们的最新研究进展,他们发现lncRNA的一个亚型--假性基因可以作为竞争性内源RNA(ceRNA)促进BRAF表达和MAPK激活,导

Cell惊人发现:会传染的癌症

数十年来,白血病爆发毁灭了北美东海岸的一些软壳蛤(soft-shell clams)种群,其却是由于恶性肿瘤细胞从一个蛤传播至另一个蛤所导致。在4月9日的Cell杂志上,研究人员将之称作为是“惊人至极”的一个研究发现。霍华德休斯医学研究所和哥伦比亚大学的Stephen Goff说:“证据表明肿瘤细胞自身具有传染性,在海洋中这些细胞可从一个动物传播至另一个动物处。williamhill asia 知道这一定是真实的,因为肿瘤细胞

Molecular cell:caspase3——抗癌卫士的“背叛”

近日,国际学术期刊molecular cell在线发表了美国杜克大学华人科学家Chuan-Yuan Li研究组的最新研究进展,他们发现之前一直认为具有抗癌作用的细胞凋亡关键效应因子caspase-3并不能有效地起到抗癌作用,更加令人意想不到的是,caspase-3会促进放射和化疗过程中的细胞遗传不稳定,在肿瘤转化中发挥重要作用。   细胞凋亡一直被看作典型的抗癌过程,在凋亡过程中ca

Developmental Cell:胰岛素干扰触发癌症恶病质

许多癌症患者遭受衰弱综合征,又称为恶病质,整个身体肌肉和脂肪组织破坏。发表在最近的Development Cell上两项使用果蝇为模型研究表示一个肿瘤分泌的蛋白质Impl2,能够抑制全身胰岛素信号,并且可能是驱动恶病质的罪魁祸首。肌肉消瘦和能量存储的损失发生在与癌症相关的恶病质,但也可以由严重饥饿,感染,或响应于创伤触发。之前已经有研究通过移植肿瘤建立这种恶病质果蝇模型,不过很少有人了解,局部肿瘤

Cell:癌症治疗路在何方

自1971年美国总统尼克松对癌症宣战以来,科学家们一致在寻找让细胞失控的基因删除、插入和重复。不断扩大的突变库帮助人们开发出了靶向性药物,将相应患者的生命延长了几个月甚至几年。但这并不是治疗癌症的唯一途径,德克萨斯大学MD Anderson癌症中心的James P. Allison和Padmanee Sharma指出。他们在四月九日的Cell杂志上发表综述文章,探讨了癌症治疗的现状和未来的发展方向

Cell:iPSC——家族性癌症研究新模型

最近利用诱导多能干细胞技术对人类疾病进行体外建模已经成为一种可行方法。来自美国的科学家利用李弗劳明综合征病人的体细胞建立了诱导多能干细胞,并利用该细胞系向osteoblast方向分化,进行了相关基因表达分析,发现分化后的细胞系能够很好的模拟骨肉瘤的肿瘤特征。最近,相关研究成果发表在著名国际学术期刊 Cell。 研究人员从患有一种p53基因突变性家族疾病(李弗劳明综合征)的病人身上获得细胞进行